Profile data is unavailable for this security.
About the company
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. is a China-based company principally engaged in the research and development, production and sales of heparin-related products. The Company's main products include standard heparin raw materials, low molecular weight heparin raw materials and their preparations, such as heparin sodium raw materials, heparin sodium, enoxaparin sodium injection, dalteparin sodium injection and Naqu Heparin Calcium Injection. The Company mainly exports its products to the United States and European countries.
- Revenue in CNY (TTM)3.88bn
- Net income in CNY-422.97m
- Incorporated2000
- Employees1.45k
- LocationNanjing King-friend Biochemical Pharmaceutical Co LtdNo. 16 Xuefu RoadHigh-tech Industrial Development ZoneNANJING 210061ChinaCHN
- Phone+86 2 586990789
- Fax+86 2 586990701
- Websitehttps://www.nkf-pharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shandong Buchang Pharmaceuticals Co Ltd | 11.78bn | -293.31m | 18.80bn | 8.31k | -- | 1.68 | -- | 1.60 | -0.2619 | -0.2619 | 10.76 | 10.09 | 0.5777 | 1.08 | 9.78 | 1,416,955.00 | -2.26 | 3.26 | -3.13 | 4.72 | 58.25 | 74.71 | -3.92 | 4.85 | 0.5070 | 0.1602 | 0.2675 | 121.01 | -11.41 | -0.6219 | 120.85 | -29.93 | -16.56 | -36.72 |
| Joincare Pharmaceutical Group Ind. Co. | 15.89bn | 1.47bn | 21.91bn | 14.37k | 14.60 | 1.51 | -- | 1.38 | 0.8006 | 0.8006 | 8.65 | 7.73 | 0.4419 | 2.27 | 5.66 | 1,106,434.00 | 8.45 | 8.46 | 17.58 | 18.84 | 61.96 | 62.72 | 19.13 | 17.00 | 1.94 | -- | 0.2241 | 28.86 | -2.90 | 8.24 | -3.99 | 15.58 | 11.53 | 2.38 |
| Tianjin Pharmcetl Da Ren Tang Grp Cp Ltd | 8.04bn | 932.37m | 22.41bn | 4.62k | 27.86 | 4.03 | -- | 2.79 | 1.21 | 1.21 | 10.42 | 8.34 | 0.7567 | 2.64 | 3.24 | 1,740,681.00 | 8.66 | 8.96 | 13.55 | 12.80 | 45.80 | 40.82 | 11.44 | 10.67 | 1.31 | -- | 0.2047 | 56.93 | -0.3266 | 5.28 | 14.49 | 11.93 | -4.33 | 42.22 |
| Tasly Pharmaceutical Group Co Ltd | 8.57bn | 880.84m | 22.47bn | 9.22k | 25.59 | 1.77 | -- | 2.62 | 0.5878 | 0.5878 | 5.73 | 8.51 | 0.4964 | 1.73 | 8.48 | 928,676.30 | 4.89 | 5.47 | 6.14 | 7.25 | 65.28 | 48.42 | 9.86 | 8.94 | 2.19 | 3.89 | 0.1766 | 50.99 | 0.4236 | -13.57 | 505.34 | -7.07 | -3.03 | 1.92 |
| China Resources Dubl-Crne Phrmctl Co Ltd | 11.22bn | 1.65bn | 22.95bn | 12.27k | 13.74 | 2.25 | -- | 2.04 | 1.61 | 1.61 | 10.93 | 9.81 | 0.7106 | 3.04 | 6.08 | 914,865.00 | 10.54 | 8.40 | 14.70 | 11.08 | 56.34 | 58.19 | 14.83 | 11.98 | 1.26 | -- | 0.0633 | 35.91 | 6.20 | 4.44 | 12.96 | 6.60 | 21.46 | -1.63 |
| Nanjing King-Frind Bchmcl Phrmctcl C Ltd | 3.88bn | -422.97m | 23.15bn | 1.45k | -- | 3.69 | -- | 5.97 | -0.3269 | -0.3269 | 2.43 | 3.88 | 0.3774 | 0.5012 | 4.35 | 2,672,280.00 | -4.12 | 8.97 | -5.76 | 13.15 | 41.00 | 45.59 | -10.91 | 20.12 | 1.51 | -2.96 | 0.269 | 26.33 | 5.89 | 18.25 | -117.37 | -- | 38.32 | 13.75 |
| Shanghai Junshi Biosciences Co Ltd | 1.79bn | -1.80bn | 26.02bn | 2.53k | -- | 4.87 | -- | 14.56 | -1.83 | -1.83 | 1.81 | 6.26 | 0.1593 | 0.8406 | 4.29 | 695,986.10 | -17.55 | -18.87 | -21.98 | -23.11 | 69.07 | 69.13 | -110.18 | -88.41 | 1.75 | -67.73 | 0.3065 | -- | 3.38 | 248.39 | 4.38 | -- | 8.36 | -- |
| Zhejiang Huahai Pharmaceutical Co., Ltd. | 9.35bn | 1.14bn | 27.11bn | 8.22k | 23.78 | 3.08 | -- | 2.90 | 0.7772 | 0.7772 | 6.34 | 5.99 | 0.4922 | 1.02 | 3.51 | 1,137,186.00 | 6.01 | 5.67 | 8.37 | 8.07 | 61.97 | 60.52 | 12.21 | 11.61 | 0.7919 | 6.25 | 0.4541 | 33.55 | 0.5199 | 10.28 | -28.88 | 50.51 | 7.21 | -- |
| Hubei Jumpcan Pharmaceutical Co Ltd | 8.92bn | 2.78bn | 27.54bn | 5.23k | 9.86 | 1.96 | -- | 3.09 | 3.03 | 3.03 | 9.71 | 15.27 | 0.5135 | 3.08 | 4.60 | 1,706,101.00 | 16.04 | 16.23 | 20.68 | 20.88 | 78.36 | 82.64 | 31.23 | 24.42 | 3.55 | -- | 0.1024 | 41.76 | 7.32 | 6.02 | 30.04 | 10.83 | -14.70 | 1.11 |
Data as of Sep 13 2024. Currency figures normalised to Nanjing King-friend Biochemical Pharmaceutical Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
13.18%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Aegon-Industrial Fund Management Co., Ltd.as of 30 Jun 2023 | 67.81m | 4.20% |
| E Fund Management Co., Ltd.as of 30 Sep 2024 | 33.15m | 2.05% |
| Invesco Great Wall Fund Management Co. Ltd. (Invt Mgmt)as of 30 Jun 2024 | 31.96m | 1.98% |
| HuaAn Fund Management Co., Ltd.as of 30 Jun 2024 | 27.27m | 1.69% |
| Bank of Communications Schroder Fund Management Co., Ltd.as of 30 Jun 2024 | 21.30m | 1.32% |
| Zhong Ou Asset Management Co., Ltdas of 30 Jun 2024 | 9.72m | 0.60% |
| Qian Hai Life Insurance Co., Ltd.as of 30 Jun 2023 | 7.33m | 0.45% |
| China Southern Asset Management Co., Ltd.as of 30 Jun 2024 | 6.51m | 0.40% |
| ICBC Credit Suisse Asset Management Co., Ltd.as of 30 Jun 2024 | 4.88m | 0.30% |
| Guotai Asset Management Co., Ltd.as of 30 Jun 2024 | 2.85m | 0.18% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
